[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,180
Citations 0
Invited Commentary
September 4, 2019

Pancreatic Ductal Adenocarcinoma—ESPAC…or It’s Back?

Author Affiliations
  • 1Perelman School of Medicine, University of Pennsylvania, Philadelphia
JAMA Surg. 2019;154(11):1048. doi:10.1001/jamasurg.2019.3364

In this issue of JAMA Surgery, Jones et al1 provide a detailed accounting of recurrence patterns of pancreatic ductal adenocarcinoma (PDAC) following resection. While not the primary aim of the European Study Group for Pancreatic Cancer (ESPAC)–4 randomized clinical trial,2 recurrence of PDAC was analyzed for 732 patients receiving adjuvant gemcitabine alone or gemcitabine plus capecitabine. Although these agents have essentially become obsolete with the adoption of FOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and irinotecan) for treatment of PDAC, the current study manages to provoke many curiosities.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words